Bonesupport Holding (BONEXS) Stock Overview
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BONEXS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Bonesupport Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 230.00 |
| 52 Week High | SEK 297.40 |
| 52 Week Low | SEK 175.60 |
| Beta | 0.48 |
| 1 Month Change | 4.69% |
| 3 Month Change | n/a |
| 1 Year Change | -25.35% |
| 3 Year Change | n/a |
| 5 Year Change | 205.44% |
| Change since IPO | 514.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| BONEXS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 1.1% | -2.7% | -1.8% |
| 1Y | -25.3% | -22.2% | 15.2% |
Return vs Industry: BONEXS underperformed the UK Biotechs industry which returned -22.2% over the past year.
Return vs Market: BONEXS underperformed the UK Market which returned 15.2% over the past year.
Price Volatility
| BONEXS volatility | |
|---|---|
| BONEXS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: BONEXS's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine BONEXS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 171 | Torbjorn Skold | www.bonesupport.com |
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally. The company offers CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; and CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also provides CERAMENT Bead Tray, an adjunctive local delivery option for surgeons desiring targeted delivery to osseous defects and for dead space management.
Bonesupport Holding AB (publ) Fundamentals Summary
| BONEXS fundamental statistics | |
|---|---|
| Market cap | SEK 14.29b |
| Earnings (TTM) | SEK 213.91m |
| Revenue (TTM) | SEK 1.29b |
Is BONEXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BONEXS income statement (TTM) | |
|---|---|
| Revenue | SEK 1.29b |
| Cost of Revenue | SEK 102.32m |
| Gross Profit | SEK 1.18b |
| Other Expenses | SEK 970.20m |
| Earnings | SEK 213.91m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
Oct 22, 2026
| Earnings per share (EPS) | 3.27 |
| Gross Margin | 92.05% |
| Net Profit Margin | 16.63% |
| Debt/Equity Ratio | 0% |
How did BONEXS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/14 12:23 |
| End of Day Share Price | 2026/09/08 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bonesupport Holding AB (publ) is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Erik Cassel | Danske Bank |
| Kristofer Liljeberg-Svensson | DNB Carnegie |